In This Section
Procedure Standards
The procedure standards help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of procedure standards will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some standards were formally adopted by SNMMI in collaboration with other professional organizations.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Practice Guidelines were renamed Procedure Standards in February 2014. This change was initiated in an effort to better reflect the terminology being used by external organizations. Any previous Practice Guideline or Procedure Guideline that describes how to perform a procedure is now considered an SNMMI Procedure Standard.
To view a section of SNMMI's Procedure Standards, please click the link(s) below:
Comments or Questions?
The SNMMI Committee on Procedure Standards is continually developing new standards and reviewing and updating existing procedure standards. If you have specific comments or questions on the content of any of the standards, or if you have suggestions for new standards that you feel should be written, please contact the SNMMI Committee on Procedure Standards here. All comments will be considered in the procedure standards development process.
Procedure Standards Available for Public Comment |
|
Comments Due By
|
Document Title
|
|
As part of the revision or development process, the SNMMI Committee on Procedure Standards will seek public comment on draft documents in order to ensure we are creating the most accurate guidelines. Please submit comments to quality@snmmi.org. Below are guidelines currently for which we are seeking public input: |
|
Recently Approved Procedure Standards |
|
Date Approved |
Document Title |
| August 25, 2023 |
International EANM‑SNMMI‑ISMRM Consensus Recommendation for PET/MRI in Oncology |
| July 4, 2023 | |
| June 23, 2023 | |
| June 14, 2023 | |
| January 27, 2023 | |
| January 9, 2023 |
PSMA PET/CT: Joint EANM Procedure Guideline/SNMMI Procedure Standard for Prostate Cancer Imaging 2.0 |
| October 8, 2022 | |
| April 30, 2022 | |
| April 30, 2022 | SNMMI Procedure Standard/EANM Practice Guideline for SSTR Receptor PET: Imaging Neuroendocrine Tumors |
| January 28, 2022 | SNMMI Procedure Standard / EANM Practice Guideline for Molecular Breast Imaging with Dedicated Gamma-Cameras |
| January 28, 2022 | SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer |
| January 28, 2022 | Joint EANM/SIOPE/RAPNO Practice Guidelines/SNMMI Procedure Standards for Imaging of Paediatric Gliomas Using PET with Radiolabelled Amino Acids and [18F]-FDG: Version 1.0. |
Click Here to View Consensus Guidelines and Position Statements |
|
Procedure Standards Under Development |
|
| SNMMI Procedure Standard/EANM Practice Guideline for FDG PET/CT Brain Imaging v 2.0 | |
| SNMMI Procedure Standard/EANM Practice Guideline for Imaging for Renal Masses | |
| SNMMI Procedure Standard/EANM Practice Guideline for PET Imaging with Fibroblast Activation Protein (FAP) | |
| SNMMI Procedure Standard/EANM Practice Guideline for Brain Death Scintigraphy v 2.0 | |
| EANM Practice Guideline/SNMMI Procedure Standard for Imaging and Therapy of Meningiomas Using Radiolabelled Somatostatin Receptor Ligands | |
| EANM Practice Guideline/SNMMI Procedure Standard for Practical Guideline on Somatostatin Receptor-Targeted Radionuclide Therapy of Neuroendocrine Tumors | |
| EANM Practice Guideline/SNMMI Procedure Standard for FDG use in Inflammation and Infection | |
| EANM Practice Guideline/SNMMI Procedure Standard in the Role of FDG PET/CT in Diagnosis, Staging, Prognostic Value, Therapy Assessment, and Restaging of Breast Cancer | |
| EANM Practice Guideline/SNMMI Procedure Standard on Tau PET Imaging in Alzheimer’s Disease | |
| SNMMI Procedure Standard/EANM Practice Guideline for Bone Scintigraphy v 4.0 | |
| EANM Practice Guideline/SNMMI Procedure Standard Bone Hybrid Imaging in Paediatrics | |
| EANM/SNMMI Position Paper on the Use of FDG in Pediatric Infection & Inflammation | |
| ANM/EANO/RANO Practice Guidelines/SNMMI Procedure Standard for Imaging and Therapy of Meningiomas Using Radiolabelled Somatostatin Receptor Ligands | |
Cardiovascular System |
|
Date Approved |
Document Title |
| March 29, 2020 | |
|
October 1, 2009 |
|
|
|
Click Here to View Consensus Guidelines and Position Statements on Cardiovascular System |
Endocrine System |
|
Date Approved |
Document Title |
|
January 25, 2020 |
|
|
June 22, 2019 |
|
|
March 30, 2019 |
|
|
September 17, 2011 |
|
| October 1, 2009 | ACR-SNMMI-SPR Practice Guideline for the Performance of Parathyroid Scintigraphy |
|
October 1, 2009 |
ACR-SNMMI-SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements |
Gastrointestinal System |
|
Date Approved |
Document Title |
| November 17, 2014 | Gastrointestinal Bleeding Scintigraphy 2.0 |
| June 5, 2014 |
Meckel Diverticulum Scintigraphy 2.0 - Original Article - Article Erratum |
| September 29, 2013 | Small-Bowel and Colon Transit 1.0* |
| October 1, 2010 | ACR-SNMMI-SPR Practice Guideline for Performance of Gastrointestinal Scintigraphy |
|
October 1, 2010 |
ACR-SNMMI-SPR Practice Guideline for the Performance of Liver and Spleen Scintigraphy |
|
June 4, 2010 |
|
|
February 8, 2009 |
|
|
Click Here to View Consensus Guidelines and Position Statements on Gastrointestinal System
|
|
Genitourinary System |
|
Date Approved |
Document Title |
| May 6, 2020 |
FDG-PET/CT External Beam Radiotherapy Treatment Planning in Uterine Cervical Cancer |
| September 28, 2019 |
[18F]Fluciclovine PET/CT for Prostate Cancer Imaging; Version 1.0 |
| June 21, 2018 | |
| June 22, 2018 | |
| January 27, 2018 |
Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0 |
| October 1, 2010 |
ACR-SNMMI-SPR Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography |
| June 20, 2003 | |
General |
|
Date Approved |
Document Title |
|
November 25, 2013 |
|
|
June 8, 2012 |
|
|
October 1, 2011 |
ACR-SNMMI Technical Standard for Diagnostic Procedures Using Radiopharmaceuticals |
|
September 12, 2010 |
|
|
June 1, 2007 |
|
|
April 30, 2006 |
|
|
Click Here to View Consensus Guidelines and Position Statements
|
|
Infection and Inflammation |
|
Date Approved |
Document Title |
| January 27, 2018 | FDG-PET/CT(A) Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica |
| November 15, 2012 | 18F-FDG Use in Inflammation and Infection |
|
October 1, 2009 |
ACR-SNMMI-SPR Practice Guideline for the Performance of Scintigraphy for Inflammation or Infection |
|
June 2, 2004 |
|
|
June 2, 2004 |
99mTc Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation 3.0 |
|
June 2, 2004 |
111In-Leukocyte Scintigraphy for Suspected Infection/Inflammation 3.0 |
Skeletal System |
|
Date Approved |
Document Title |
|
June 21, 2018 |
|
|
June 4, 2010 |
|
Central Nervous System |
|
Date Approved |
Document Title |
|
January 25, 2020 |
|
|
January 30, 2016 |
|
|
June 8, 2012 |
|
|
February 8, 2009 |
|
|
February 8, 2009 |
|
Oncology |
|
Date Approved |
Document Title |
|
September 14, 2021 |
2-[18F]FDG PET/CT External Beam Radiation Treatment Planning in Lung Cancer V1.0 |
|
September 22, 2018 |
Imaging of Gliomas Using PET with Radiolabelled Amino Acids and [18F]FDG: Version 1.0 |
|
June 22, 2018 |
|
|
March 10, 2017 |
|
|
July 7, 2015 |
Lymphoscintigraphy and Sentinel Lymph Node Biopsy in Melanoma – SNMMI Endorsement |
|
February 7, 2014 |
Lymphoscintigraphy and Sentinel Node Localization in Gynecological Cancers – SNMMI Endorsement |
|
September 29, 2013 |
Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer |
|
September 22, 2012 |
131I/123I- Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging – SNMMI Endorsement** |
|
June 4, 2010 |
|
|
June 2, 2004 |
|
|
Click Here to View Consensus Guidelines and Position Statements on Oncology
|
|
Pediatric |
|
Date Approved |
Document Title |
| May 24, 2021 | Pediatric [99mTc]Tc-DMSA Renal Cortical Scintigraphy: An Update |
| March 29, 2020 | Pediatric [18F]FDG PET-CT for Oncology 1.0 |
| October 28, 2013 | Pediatric Radiopharmaceutical Administration: Harmonization |
| October 26, 2010 | Pediatric Dose Consensus Guidelines |
| *Based on the findings of a survey conducted at 13 premier pediatric hospitals in North America indicating administered radiopharmaceutical activities in children varied greatly, a workgroup was established representing the Society of Nuclear Medicine and Molecular Imaging (SNMMI) through the Pediatric Council, the Society for Pediatric Radiology and the Amercian College of Radiology (ACR). The Workgroup achieved concensus on pediatric administered radiopharmaceutical doses for 11 commonly used radiopharmaceuticals. | |
|
October 1, 2010 |
ACR-SNMMI-SPR Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography |
|
October 1, 2009 |
|
|
January 25, 2003 |
|
|
January 25, 2003 |
|
Pulmonary System |
|
Date Approved |
Document Title |
|
July 19, 2011 |
|
|
October 1, 2009 |
|
Therapy |
|
Date Approved |
Document Title |
| August 4, 2019 |
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy with Radium-223 |
| January 18, 2019 |
Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE |
| June 8, 2012 | |
| March 20, 2012 | Radioimmunotherapy for B-cell lymphoma with 90Y-radiolabelled itribumomab tiuxetan (Zevalin) – SNMMI Endorsement** |
| * Pretherapeutic imaging with 111In-ibritumomab tiuxetan is no longer mandatory in the United States. | |
**Regulatory Issues for EANM GuidelinesApplicable to all countries: Clinicians involved in unsealed source therapy must be knowledgeable about and compliant with all applicable national and local legislation and regulations. Applicable in the United States: The radiopharmaceutical(s) used for the diagnostic and therapeutic procedure(s) addressed in this guideline/guidance document is/are not approved by the Food and Drug Administration (FDA)in the United States. Therefore in the United States, these procedures should be performed only by physicians holding an FDA-approved Investigational New Drug (IND) application for the radiopharmaceutical. |
|
|
|
|
Retired Procedure Standards |
|
|
Please note the below procedure standards have been retired and thus not updated since their last approval. Therefore, these standards may not reflect current knowledge and practice in the field of nuclear medicine. SNMMI is providing these procedures on an 'as is' basis for general information purposes only and does not accept any responsibility for accuracy, completeness, currency, relevance, reliability or suitability of the information contained therein. |
|
Date Approved |
Document Title |
|
January 25, 2013 |
Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors |
|
November 15, 2012 |
|
|
July 19, 2011 |
|
|
October 26, 2011 |
|
|
June 14, 2008 |
|
|
February 11, 2006 |
|
|
September 5, 2006 |
|
|
January 25, 2003 |
|
|
June 20, 2003 |
|
|
June 23, 2001 |
Gallium Scintigraphy in the Evaluation of Malignant Disease 3.0 |
|
February 7, 1999 |
|
|
February 7, 1999 |
Gastrointestinal Bleeding/Meckel's Diverticulum Scintigraphy 1.0 |
Feedback
Please let us know if you have any suggestions for future topics for AUC development, or any feedback on the existing publications by contacting us at quality@snmmi.org.